Medtronic study shows patients with high blood pressure are interested in an interventional procedure treatment option

New data from medtronic patient preference study presented at tct 2021; medtronic adds to its clinical leadership for renal denervation with launch of the spyral affirm study dublin and orlando, fla., nov. 4, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced findings from a new study of the patient preferences for the treatment of hypertension.
MDT Ratings Summary
MDT Quant Ranking